Gain Context, Insight and Value from Big Content

To reduce the impact of an unfolding crisis, companies need a clear, accurate and early line of sight into emerging risks. Leaders can then act with confidence and seize opportunities to preserve brand reputation while driving operational excellence. To demonstrate how real-time information can help companies gain advanced warn

According to the Office for National Statistics, in April 2020, the number of remote workers increased to 46% of the population. Now with the easing of lockdown measures, many businesses are considering or are already implementing what the Financial Times calls a "split model' a.k.a "hybrid working" that divides the time between the home and the office. If home-office working is to become the norm, then organisations need to consider the data protection challenges they will be faced with.

According to PwC, nearly 4 out of 5 CEOs believe that remote collaboration will last after the pandemic. And Gartner predicts that through 2025, 80% of organizations trying to scale digital business will fail because they don’t take a modern approach to data and analytics governance.

The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®) is launching a new webinar series with the goal of sharing with the community examples of the use of rare disease person-level data in drug development and regulatory decision making. The series will feature 1-hour webinars highlighting analyses that have been done in individual disease areas, how they informed drug development, and how similar approaches could be applied to common drug development issues encountered in rare diseases. After each presentation time will be allowed for discussion with a panel of Quantitative and Regulatory experts around why the solutions presented were informative, lessons learned and how similar approaches could be applied to related problems.